CAMBRIDGE, Mass., Aug. 15, 2017 /PRNewswire/ -- Cancer
Treatment Centers of America® (CTCA) and Foundation Medicine® today
announced a new element to their longstanding partnership to
increase awareness of advancements in genomic testing and precision
medicine in oncology. The educational initiative directed toward
physicians, other caregivers and patients will highlight the
importance of integrating comprehensive genomic testing of solid
tumors early in an individual's care plan as a model to inform
personalized care and improve clinical outcomes for individuals
with cancer.
"Precision cancer treatment using advanced genomic testing is
changing the science of cancer care," said Maurie Markman, M.D., President of Medicine & Science at CTCA®.
"As oncologists, we have an obligation to the patients we serve to
keep pace with, and, whenever possible, lead the way in the
application of the latest diagnostic tools that may help inform
treatment decisions. Our partnership with Foundation Medicine
empowers our physicians to customize treatment plans according to
the individual patient's clinical profile right down to the
molecular level, and therefore furnish care in a much more
comprehensive and effective manner."
The partnership brings together CTCA, a national network of five
cancer treatment hospitals at the forefront of delivering precision
cancer treatment to address individual patients' unique treatment
needs, and Foundation Medicine, a leader in molecular information
that offers a suite of comprehensive genomic profiling (CGP) assays
that identifies the molecular alterations in an individual's cancer
and matches them with potentially relevant targeted therapies,
including immunotherapies.
Through their shared patient-centered philosophy, CTCA and
Foundation Medicine will educate the medical community about the
successful approach CTCA is using to incorporate FoundationOne® for
solid tumors into clinical care. Specifically, the educational
initiative will feature several patients with cancer, chronicling
each person's journey from cancer diagnosis to tumor profiling to
treatment. Through this case-based approach, the program aims to
provide insights into precision medicine treatment approaches based
on an individual's unique cancer, including the selection of
targeted therapies, appropriate clinical trials and responses to
immunotherapy.
"Precision medicine, and a move to a more personalized, targeted
approach to cancer care, is becoming ever more ubiquitous as the
published data continues to validate this approach as leading to
better clinical outcomes for patients," said Vincent Miller, M.D., Chief Medical Officer for
Foundation Medicine. "As such, it's critical that every stakeholder
in a patient's care plan—physician, patient and care team—is
knowledgeable about the benefits of genomic profiling, and
importantly, that they have the right tools at the ready to
implement such an approach. We applaud CTCA leadership in this area
and we're delighted to collaborate with them on this educational
initiative."
To learn more about genomics and precision cancer treatment,
visit cancercenter.com. To learn more about genomic testing and
FoundationOne, visit FoundationMedicine.com.
About Cancer Treatment Centers of
America®
Cancer Treatment Centers of America
Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of
five hospitals that serves adult patients who are fighting cancer.
CTCA® offers an integrative approach to care that combines
advancements in genomic testing and precision cancer treatment,
surgery, radiation, immunotherapy and chemotherapy, with
evidence-informed supportive therapies designed to help patients
physically and emotionally by enhancing their quality of life while
managing side effects both during and after treatment. CTCA serves
patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Reflecting our
patient-centered approach to cancer care, our patient satisfaction
scores consistently rank among the highest in the country for
cancer care providers, and CTCA is also rated one of the most
admired hospital systems in the country in national consumer
surveys. For more information, visit cancercenter.com,
Facebook.com/cancercenter and Twitter.com/cancercenter.
About Foundation Medicine®
Foundation Medicine (NASDAQ:FMI) is a molecular information
company dedicated to a transformation in cancer care in which
treatment is informed by a deep understanding of the genomic
changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling
assays to identify the molecular alterations in a patient's cancer
and match them with relevant targeted therapies, immunotherapies
and clinical trials. Foundation Medicine's molecular
information platform aims to improve day-to-day care for patients
by serving the needs of clinicians, academic researchers and drug
developers to help advance the science of molecular medicine in
cancer. For more information, please
visit http://www.FoundationMedicine.com or
follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered
trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the objectives
of any educational initiatives between CTCA and Foundation
Medicine; the importance of integrating comprehensive genomic
testing of solid tumors early in an individual's care plan to
improve clinical outcomes for individuals with cancer; and the
value and performance capabilities of Foundation Medicine's
comprehensive genomic profiling assays. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include the risk
that educational initiatives are not developed or launched in
the anticipated manner; Foundation Medicine's CGP
and services will not be able to identify genomic alterations
in the same manner as prior clinical data or prior
experience; and the risks described under the caption "Risk
Factors" in Foundation Medicine's Annual Report on Form
10-K for the year ended December 31, 2016, which is on file
with the Securities and Exchange Commission, as well as other
risks detailed in Foundation Medicine's subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Foundation Medicine undertakes no duty to update this
information unless required by law.
Contact:
Michael Myers
Cancer Treatment Centers of America®
michael.myers@ctca-hope.com
561-923-3179
Lee-Ann Murphy
Foundation Medicine
617-245-3077
pr@foundationmedicine.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/cancer-treatment-centers-of-america-and-foundation-medicine-join-forces-to-advance-precision-cancer-treatment-300504156.html
SOURCE Cancer Treatment Centers of America